Farxiga and Apixaban Interaction: What Patients and Prescribers Need to Know

What Is the Interaction Between Farxiga and Apixaban?

There is no direct pharmacokinetic drug-drug interaction between dapagliflozin and apixaban. The FDA label for dapagliflozin lists no interaction with direct oral anticoagulants (DOACs), and the apixaban prescribing information does not identify SGLT2 inhibitors as interacting agents. Clinically meaningful risk does exist, but it is pharmacodynamic and indirect, arising from the physiological effects each drug produces rather than from competition at enzyme or transporter sites.

Mechanism of Dapagliflozin

Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, blocking roughly 30 to 50 percent of filtered glucose reabsorption and producing glycosuria, mild osmotic diuresis, and natriuresis. The FDA-approved label for Farxiga (accessdata.fda.gov) confirms that dapagliflozin is metabolized primarily via UGT1A9-mediated glucuronidation to an inactive metabolite (dapagliflozin 3-O-glucuronide). It is not a meaningful inhibitor or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. [1]

Mechanism of Apixaban

Apixaban, a direct factor Xa inhibitor, relies heavily on CYP3A4 and, to a lesser extent, CYP1A2 for hepatic metabolism. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). The FDA label for Eliquis (accessdata.fda.gov) states that strong dual inhibitors of CYP3A4 and P-gp (for example, ketoconazole or ritonavir) increase apixaban exposure by approximately 2-fold, which is clinically significant. [2] Because dapagliflozin engages none of these pathways, it cannot reproduce that effect.

Why the Combination Is Still Used

Atrial fibrillation frequently co-exists with heart failure (HF) and chronic kidney disease (CKD), the two non-diabetes indications where dapagliflozin earned FDA approval. The DAPA-HF trial (N=4,744) showed dapagliflozin 10 mg reduced the composite of worsening HF or cardiovascular death by 26 percent versus placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [3] A sizable portion of those patients also required anticoagulation for atrial fibrillation, making apixaban the logical co-agent given its superior efficacy and safety profile in the ARISTOTLE trial (N=18,201). [4]

Pharmacokinetic Analysis: Does Dapagliflozin Affect Apixaban Levels?

No published dedicated pharmacokinetic study has measured apixaban plasma concentrations in subjects simultaneously taking dapagliflozin. That absence of data reflects the absence of a mechanistic rationale rather than a gap in safety surveillance. Because dapagliflozin does not touch CYP3A4, P-gp, or BCRP, its co-administration should leave apixaban area-under-the-curve (AUC) and peak concentration (Cmax) unchanged.

The Volume Depletion Caveat

Dapagliflozin produces a net volume reduction estimated at 200 to 400 mL in the first weeks of therapy, primarily through osmotic diuresis. [5] Volume contraction can theoretically increase the plasma concentration of highly protein-bound drugs by reducing the volume of distribution. Apixaban is approximately 87 percent protein-bound. Whether this produces any clinically detectable increase in apixaban exposure has not been studied in a controlled trial, and the magnitude of the volume shift is modest compared to loop diuretic effects seen in the same patient population. Prescribers should keep this mechanism in mind when a patient on apixaban is also taking a loop diuretic plus dapagliflozin, since the combined diuretic burden may be more consequential.

Renal Function and Apixaban Clearance

Roughly 27 percent of an apixaban dose is excreted renally. [2] Dapagliflozin modestly lowers eGFR in the first 2 to 4 weeks of treatment (a well-documented hemodynamic effect that later partially reverses), per the DAPA-CKD trial data. [6] If a patient's eGFR drops acutely, apixaban renal clearance decreases and exposure may rise. The Eliquis prescribing information recommends dose reduction to 2.5 mg twice daily when two of three criteria are met: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. [2] Initiating dapagliflozin in a patient already near this threshold warrants a creatinine and eGFR check within 4 weeks.

Pharmacodynamic Interactions: Bleeding and Volume Effects

Even when two drugs share no pharmacokinetic pathway, their combined physiological effects can create clinical risk. With dapagliflozin and apixaban, two pharmacodynamic concerns deserve attention.

Bleeding Risk

Apixaban inhibits factor Xa and suppresses thrombin generation, which inherently raises bleeding risk regardless of co-medications. In ARISTOTLE, apixaban produced major bleeding in 2.13 percent of patients per year versus 3.09 percent per year with warfarin (P<0.001 for superiority). [4] SGLT2 inhibitors do not inhibit platelet function and are not anticoagulants. No published large-scale dataset has shown that dapagliflozin independently raises bleeding event rates. The combination therefore carries the bleeding risk of apixaban alone, not a compounded risk, though patients should be counseled to report unusual bruising, blood in urine, or prolonged bleeding from cuts.

Urinary Tract Considerations

Dapagliflozin increases the risk of urinary tract infections (UTIs) and genitourinary fungal infections due to glycosuria. [1] Hematuria caused by a UTI in a patient on apixaban can be mistaken for anticoagulant-related bleeding. Clinicians should include urinalysis as part of hematuria workup in this combination rather than immediately attributing blood in urine to apixaban-related hemorrhagic cystitis or over-anticoagulation.

Hypotension and Falls

Dapagliflozin lowers blood pressure by 3 to 5 mmHg systolic on average, likely through volume and natriuresis effects. [7] Apixaban itself does not affect blood pressure, but orthostatic hypotension in a volume-depleted patient on apixaban increases fall risk, and falls in anticoagulated patients carry higher morbidity. The 2023 ACC/AHA Heart Failure Guideline recommends optimizing volume status when initiating SGLT2 inhibitors in patients already on diuretics. [8]

Clinical Evidence for Co-Prescribing Dapagliflozin and Apixaban

No randomized trial has specifically examined dapagliflozin plus apixaban as a co-primary comparison. Real-world data, however, are available from large registry analyses of SGLT2 inhibitors and DOACs in heart failure populations.

DAPA-HF Subgroup Analysis

The DAPA-HF investigators allowed anticoagulant use at baseline; approximately 38 percent of enrolled patients were on an oral anticoagulant at randomization. [3] The relative risk reduction for the primary composite endpoint was consistent regardless of anticoagulant use at baseline, suggesting dapagliflozin's benefit is preserved when co-prescribed with anticoagulants and that safety was not materially compromised in that subgroup.

EMPA-REG and Class-Effect Reasoning

While not a dapagliflozin-specific trial, EMPA-REG OUTCOME (N=7,020, empagliflozin vs. Placebo in type 2 diabetes with cardiovascular disease) demonstrated a 38 percent relative risk reduction in cardiovascular death. [9] Anticoagulant use was common in that cohort, and no excess bleeding signal was attributed to the combination, supporting a class-level inference that SGLT2 inhibitors do not amplify anticoagulant bleeding risk in large trial populations.

AHA Scientific Statement on DOACs in Heart Failure

The American Heart Association's 2023 scientific statement on antithrombotic therapy in heart failure notes that DOACs, particularly apixaban, are preferred over warfarin in patients with HF and atrial fibrillation, citing lower intracranial hemorrhage rates and more predictable pharmacokinetics. [8] The statement does not identify SGLT2 inhibitors as agents requiring DOAC dose modification, which aligns with the pharmacokinetic reasoning above.

Monitoring Protocol When Dapagliflozin and Apixaban Are Co-Prescribed

A structured monitoring approach reduces residual risk from indirect pharmacodynamic effects. The following framework applies at initiation and during ongoing therapy.

At Initiation (Week 0 to 4)

Obtain a baseline metabolic panel including serum creatinine, eGFR, serum potassium, and hematocrit before starting dapagliflozin. Recheck creatinine and eGFR at 2 to 4 weeks after initiation. If eGFR declines more than 30 percent from baseline, reassess apixaban dosing eligibility criteria (age, weight, creatinine) before continuing both drugs. Document blood pressure lying and standing to identify orthostatic hypotension, particularly in patients already on an ACE inhibitor or ARB. [1, 6]

Ongoing Monitoring (Every 3 to 6 Months)

Renal function should be checked every 3 to 6 months in patients with CKD stage 3 or worse, since both the DAPA-CKD trial protocol and the FDA label for Farxiga recommend periodic renal monitoring. [6] At each visit, ask specifically about signs of bleeding (unusual bruising, blood in stool, prolonged bleeding), genitourinary symptoms that might indicate a UTI causing hematuria, and symptoms of volume depletion (lightheadedness on standing, excessive thirst). Hematocrit typically rises 2 to 3 percentage points with SGLT2 inhibitor therapy due to hemoconcentration, an effect documented in the DAPA-HF trial. [3] A rising hematocrit in the setting of apixaban does not indicate bleeding; it is expected.

When to Reassess Apixaban Dosing

Reassess apixaban dose only if the patient meets the standard Eliquis dose-reduction criteria (two of three: age 80+, weight 60 kg or less, creatinine 1.5 mg/dL or higher) or if eGFR falls below 25 mL/min/1.73 m2, at which point apixaban has limited trial data and alternative anticoagulation strategies should be discussed. [2, 10]

Dapagliflozin Drug Interactions: Broader Context

Beyond apixaban, understanding dapagliflozin's full interaction profile helps prescribers anticipate where actual pharmacokinetic risks lie.

Insulin and Sulfonylureas

The most clinically significant interaction for dapagliflozin is pharmacodynamic, not pharmacokinetic. Combining dapagliflozin with insulin or a sulfonylurea increases hypoglycemia risk. The FDA label states that when initiating Farxiga in patients on insulin, a dose reduction of insulin or the insulin secretagogue may be required. [1] This is separate from the apixaban question but relevant when patients carry all three drugs.

Diuretics

Loop diuretics and thiazides combined with dapagliflozin magnify volume depletion and increase the risk of acute kidney injury, which secondarily affects apixaban clearance as described above. The prescribing information for both furosemide and dapagliflozin advises monitoring for dehydration when these are combined. [1]

CYP3A4 Inhibitors That Affect Apixaban, Not Dapagliflozin

Drugs that raise apixaban exposure do so through CYP3A4 and P-gp inhibition, not through SGLT2-related pathways. Azole antifungals (for example, fluconazole 200 mg daily raises apixaban AUC by approximately 1.4-fold per pharmacokinetic studies), clarithromycin, diltiazem, and HIV protease inhibitors are examples that affect apixaban. [2, 11] Adding one of these to a patient already on dapagliflozin plus apixaban raises apixaban exposure and requires dose review; dapagliflozin itself remains uninvolved.

P-gp Inducers

Rifampin reduces apixaban AUC by approximately 54 percent and is contraindicated with apixaban per its label. [2] Carbamazepine, phenytoin, and St. John's Wort have similar inducer effects. None of these interact with dapagliflozin's UGT1A9 pathway. When a clinician adds or removes a P-gp inducer from the regimen, apixaban exposure changes substantially regardless of whether dapagliflozin is present.

Patient Counseling Points

Patients prescribed both Farxiga and apixaban should receive specific, actionable guidance, not generic "watch for side effects" language.

Hydration

Drink approximately 6 to 8 cups (1.5 to 2 liters) of water daily unless fluid restriction is medically required for heart failure management. Dapagliflozin's osmotic diuresis is mild but cumulative in heat or during illness. Dehydration that causes a rise in serum creatinine can secondarily reduce apixaban clearance. [1, 6]

Bleeding Awareness

Report any of the following without delay: blood in urine that is bright red rather than pink-tinged (UTI-related hematuria is typically pink), black or tarry stools, coughing or vomiting blood, cuts that do not stop bleeding within 10 minutes of pressure, or severe or unusual bruising. These are standard apixaban counseling points that apply regardless of dapagliflozin co-use. [2]

Sick-Day Rules

Hold dapagliflozin during illness causing vomiting, diarrhea, or inability to eat, since euglycemic diabetic ketoacidosis (euDKA) has been reported with SGLT2 inhibitors under stress conditions. The FDA issued a safety communication in 2015 on this risk. [12] Patients on both drugs who develop an acute illness should contact their prescriber to determine whether to hold dapagliflozin temporarily while continuing apixaban.

Over-the-Counter NSAIDs

NSAIDs raise both acute kidney injury risk (via prostaglandin inhibition, which magnifies SGLT2-related volume effects) and bleeding risk (via platelet inhibition, which compounds apixaban's anticoagulation). Patients on this combination should avoid ibuprofen, naproxen, and similar agents unless directed by their physician. [13]

Special Populations

Heart Failure With Reduced Ejection Fraction

This is the population where dapagliflozin and apixaban most frequently co-exist. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives a Class I recommendation to SGLT2 inhibitors in symptomatic HFrEF to reduce hospitalization and mortality, and separately recommends anticoagulation for patients with concurrent atrial fibrillation. [8] Both recommendations stand independently; one does not modify the other.

Chronic Kidney Disease

In DAPA-CKD (N=4,304), dapagliflozin 10 mg reduced the composite of sustained eGFR decline of 50 percent or more, end-stage kidney disease, or renal or cardiovascular death by 39 percent versus placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001). [6] Patients with CKD who also have atrial fibrillation require careful apixaban dose monitoring as renal function changes over time. The FDA label for Eliquis advises that patients with end-stage renal disease on dialysis may receive apixaban at 5 mg twice daily with dose reduction considerations. [2]

Older Adults (Age 75 and Older)

Volume depletion from dapagliflozin carries greater consequences in older adults: higher fall risk, greater susceptibility to acute kidney injury, and lower physiological reserve. Combined with apixaban, falls carry added hemorrhagic risk. The 2019 American Geriatrics Society Beers Criteria cautions against initiating strong anticoagulants in patients with high fall risk without a formal risk-benefit discussion, and adds that SGLT2 inhibitors require assessment of volume status in frail older patients. [14] This does not prohibit the combination but does call for more frequent monitoring and a lower threshold for dose adjustment.

Type 2 Diabetes With Atherosclerotic Cardiovascular Disease

In DECLARE-TIMI 58 (N=17,160), dapagliflozin did not significantly reduce the primary MACE endpoint in the overall population (hazard ratio 0.93; 95% CI 0.84 to 1.03) but did significantly reduce the composite of cardiovascular death or HF hospitalization (hazard ratio 0.83; 95% CI 0.73 to 0.95; P=0.005). [15] Anticoagulant use was permitted in DECLARE-TIMI 58, and no safety signal emerged from the subgroup of patients on anticoagulants.